{"id":"levosimendan-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Arrhythmias"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levosimendan binds to cardiac troponin C and enhances the interaction between actin and myosin filaments, thereby increasing myocardial contractility. Simultaneously, it opens ATP-sensitive potassium channels in vascular smooth muscle, leading to vasodilation and reduced cardiac afterload. This dual mechanism improves cardiac output while reducing myocardial oxygen demand.","oneSentence":"Levosimendan is a calcium sensitizer that increases the force of cardiac muscle contraction without increasing oxygen consumption, while also causing vasodilation through opening of ATP-sensitive potassium channels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:03.773Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute decompensated heart failure"},{"name":"Cardiogenic shock"}]},"trialDetails":[{"nctId":"NCT05664191","phase":"PHASE2","title":"Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-13","conditions":"Sub-arachnoid Haemorrhage","enrollment":30},{"nctId":"NCT03624010","phase":"PHASE2","title":"Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients","status":"COMPLETED","sponsor":"Tenax Therapeutics, Inc.","startDate":"2018-11-14","conditions":"Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction","enrollment":20},{"nctId":"NCT04020263","phase":"PHASE3","title":"Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock","status":"RECRUITING","sponsor":"Pr Bruno LEVY","startDate":"2023-07-03","conditions":"Cardiogenic Shock","enrollment":610},{"nctId":"NCT04329624","phase":"PHASE3","title":"Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2020-10-10","conditions":"Cardiovascular Risk Factor","enrollment":230},{"nctId":"NCT03541603","phase":"PHASE2","title":"Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF","status":"COMPLETED","sponsor":"Tenax Therapeutics, Inc.","startDate":"2018-11-14","conditions":"Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction","enrollment":44},{"nctId":"NCT06387862","phase":"PHASE2","title":"Pharmacokinetics of Inhaled Levosimendan","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2024-02-01","conditions":"Left Ventricular Dysfunction","enrollment":6},{"nctId":"NCT06196177","phase":"PHASE4","title":"Effects of Levosimendan on Cardiac Function After TAVR in Patients With Heart Failure","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-03-01","conditions":"Heart Failure, Aortic Stenosis, Severe","enrollment":112},{"nctId":"NCT05956431","phase":"PHASE4","title":"RCT Study of Levosimendan Improving Prognosis of Cardiac Arrest","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-08-01","conditions":"Heart Arrest","enrollment":60},{"nctId":"NCT05768230","phase":"PHASE2, PHASE3","title":"Using TEE to Evaluate the Effect of Levosimendan on Patients With ARDS Associated With RVD During MV","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-03-22","conditions":"Transesophageal Echocardiography, Acute Respiratory Distress Syndrome, Right Ventricular Dysfunction","enrollment":58},{"nctId":"NCT05658692","phase":"PHASE4","title":"Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-10-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":1000},{"nctId":"NCT04970238","phase":"PHASE4","title":"Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction","status":"UNKNOWN","sponsor":"Zhijun Sun","startDate":"2021-10","conditions":"ST Elevation Myocardial Infarction, Heart Failure","enrollment":500},{"nctId":"NCT04950569","phase":"PHASE4","title":"Effect of Levosimendan on miRNAs Regulation in the Failing Hearts","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2020-10-29","conditions":"Heart Failure","enrollment":136},{"nctId":"NCT03659851","phase":"","title":"Levosimendan In Patients Undergoing LVAD Implantation","status":"UNKNOWN","sponsor":"University Hospital Dubrava","startDate":"2009-06-01","conditions":"Left Ventricular Dysfunction, Right Ventricular Dysfunction, Biventricular Failure","enrollment":50},{"nctId":"NCT01290146","phase":"PHASE3","title":"ELEVATE Early LEvosimendan Vs Usual Care in Advanced Chronic hearT failurE","status":"TERMINATED","sponsor":"Niguarda Hospital","startDate":"2011-02","conditions":"Advanced Chronic Heart Failure","enrollment":13},{"nctId":"NCT01595737","phase":"PHASE4","title":"Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery","status":"COMPLETED","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2011-02","conditions":"Cardiac Surgery","enrollment":30},{"nctId":"NCT00695929","phase":"NA","title":"Levosimendan in Congenital Cardiac Surgery","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2008-07","conditions":"Congenital Cardiovascular Defects, Low Cardiac Output Syndrome","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intervention Group"],"phase":"marketed","status":"active","brandName":"Levosimendan Injection","genericName":"Levosimendan Injection","companyName":"Peking University Third Hospital","companyId":"peking-university-third-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levosimendan is a calcium sensitizer that increases the force of cardiac muscle contraction without increasing oxygen consumption, while also causing vasodilation through opening of ATP-sensitive potassium channels. Used for Acute decompensated heart failure, Cardiogenic shock.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}